At the time of writing, Skye Bioscience Inc [SKYE] stock is trading at $1.53, up 0.66%. An important factor to consider is whether the stock is rising or falling in short-term value. The SKYE shares have lost -11.05% over the last week, with a monthly amount drifted -60.36%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Skye Bioscience Inc [NASDAQ: SKYE] stock has seen the most recent analyst activity on October 06, 2025, when Craig Hallum downgraded its rating to a Hold but kept the price target unchanged to $2 for it. Previously, Cantor Fitzgerald downgraded its rating to Neutral on October 06, 2025, and kept the price target unchanged to $2. On August 15, 2025, Evercore ISI initiated with a Outperform rating and assigned a price target of $10 on the stock. William Blair started tracking the stock assigning a Outperform rating. Scotiabank initiated its recommendation with a Sector Outperform and recommended $20 as its price target on September 30, 2024. JMP Securities started tracking with a Mkt Outperform rating for this stock on September 10, 2024, and assigned it a price target of $15. In a note dated July 09, 2024, Craig Hallum initiated a Buy rating and provided a target price of $18 on this stock.
For the past year, the stock price of Skye Bioscience Inc fluctuated between $1.14 and $5.96. Currently, Wall Street analysts expect the stock to reach $2 within the next 12 months. Skye Bioscience Inc [NASDAQ: SKYE] shares were valued at $1.53 at the most recent close of the market. An investor can expect a potential return of 30.72% based on the average SKYE price forecast.
Analyzing the SKYE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.81, Equity is -0.69 and Total Capital is -1.14. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Skye Bioscience Inc [NASDAQ:SKYE] has a current ratio of 6.09. On the other hand, the Quick Ratio is 6.09, and the Cash Ratio is 2.87.
Transactions by insiders
Recent insider trading involved Schwab Andrew J., Director, that happened on Aug 22 ’25 when 0.17 million shares were sold. Director, Schwab Andrew J. completed a deal on Aug 21 ’25 to sell 60956.0 shares. Meanwhile, 10% Owner 5AM Partners VII, LLC sold 0.17 million shares on Aug 22 ’25.
